Table 1.

Description of the drugs and indications analysed in this study

Lung cancer	Pembrolizumab	1. Monotherapy for the first-line treatment of metastatic Non-Small Cell Lung Carcinoma (NSCLC) in adults with tumours that express PD-L1 with a tumour maker proportion (TMP) ≥ 50% without positive tumour mutations o the EGFR or ALK genes 2. Monotherapy for the treatment of locally advanced or metastatic NSCLC in adults with tumours that express PD-L1 with a TPS ≥ 1% and that have received at least one previous chemotherapy treatment
	Atezolizumab	Monotherapy for the treatment of adult patients with locally advanced or metastatic Non-Small Cell Lung Carcinoma (NSCLC) that have received prior treatment with chemotherapy
	Nivolumab	Monotherapy for the treatment of adult patients with locally advanced or metastatic Non-Small Cell Lung Carcinoma (NSCLC) that have received prior treatment with chemotherapy
Breast cancer	Ribociclib	In combination with an aromatase inhibitor as an initial hormonal treatment of post-menopausal women with locally advanced or metastatic breast cancer, positive for the Hormonal Receptor (HR), and negative for the Human Epidermal Growth Factor 2 (HER2)
	Palbociclib	Treatment of metastatic or locally advanced Hormonal Receptor (HR) positive and Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer
Melanoma	Dabrafenib y Trametinib	Trametinib in combination dabrafenib for the treatment of adult patients with non-resectable or metastatic melanoma with a BRAF 600 mutation
	Cobimetinib y Vemurafenib	Cobimetinib in combination with vemurafenib for the treatment of adult patients with non-resectable or metastatic melanoma with a BRAF V600 mutation
Ovarian cancer	OLAPARIB	Monotherapy for the treatment of adult patients with BRCA-mutated (germline or somatic) advanced high-grade serous epithelial ovarian cancer, fallopian tube or primary peritoneal cancer, in relapse and sensitive to platinum, following first-line platinum-based chemotherapy (complete or partial response)